Table 2.
Effects of different types of COVID-19 vaccine on ART outcomes.
| References | Study design | Vaccine type | Sample size | Male vaccination | History of SARS CoV-2 infection | ART treatment after vaccination | Control | Main outcomes | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | [66] | Retrospective cohort study | mRNA vaccine | 72 cycles | Yes | Unknown | 7-85 days after the second dose | Self-control | No significant differences |
| 2 | [70] | Retrospective cohort study | mRNA vaccine | 84 cycles | Unknown | No | Average 131.8 days after the first dose | Unvaccinated group | No significant differences |
| 3 | [14] | Retrospective cohort study | mRNA vaccine | 230 IVF cycles | 21 of 29 males who reported vaccination information vaccinated | Unknown | >7 days after the second dose | Unvaccinated group | No significant differences |
| 4 | [7] | Retrospective cohort study | mRNA vaccine | 400 IVF cycles | Unknown | No | 14-68 days after the second dose | Unvaccinated group | No significant differences |
| 5 | [3] | Retrospective cohort study | mRNA vaccine | 1205 IVF cycles | Unknown | Unknown | >14 days after the second dose | Unvaccinated group | No significant differences |
| 6 | [40] | Retrospective cohort study | mRNA vaccine | 280 IVF cycles | Unknown | Unknown | Average 93 days after the second dose | Unvaccinated group | No significant differences |
| 7 | [5] | Retrospective cohort study | mRNA vaccine | 936 IVF cycles | Unknown | 18.4% infected in vaccinated group, none in unvaccinated group | Average 79 days after the second dose | Unvaccinated group | No significant differences |
| 8 | [42] | Retrospective cohort study | mRNA vaccine | 232 IVF cycles | Unknown | No | 1-3, 3–6, 6–9 and 9–13 months after the first dose | Unvaccinated group | No significant differences |
| 9 | [85] | Retrospective cohort study | Inactivated vaccine | 1583 IVF cycles | 80.7% vaccinated | No | ≤30 days (27.5%), 31–60 days (38.4%) and ≥61 days (34.1%) after the second dose | Unvaccinated group | No significant differences |
| 10 | [15] | Retrospective cohort study | Inactivated vaccine | 2091 IVF cycles | 70.4% vaccinated | No | Unknown | Unvaccinated group | No significant differences |
| 11 | [52] | Retrospective cohort study | Inactivated vaccine | 802 IVF cycles | 48.5% vaccinated | No | Unknown | Unvaccinated group | No significant differences |
| 12 | [36] | Retrospective cohort study | Inactivated vaccine | 133 PGT cycles | Unknown | No | Average 126.5 days after the second dose | Unvaccinated group | No significant differences |
| 13 | [50] | Retrospective cohort study | Inactivated vaccine | 730 IVF cycles | Unknown | No | Average 72.4 days after the second dose | Unvaccinated group | No significant differences |
| 14 | [73] | Prospective cohort study | Inactivated vaccine | 3052 IVF cycles | Unknown | No | ≤30 days (5.2%), 31-60 days (8.7%), 61-90 days (15.7%), and ≥91 days (70.3%) after the first dose | Unvaccinated group | Receipt of the first inactivated vaccine dose 60 days or less before fertilization treatment is associated with a reduced rate of pregnancy |
| 15 | [89] | Retrospective cohort study | 19.4% Viral vector vaccine, 79°2% inactivated vaccine, 1.4% recombinant subunit vaccine | 2505 IVF cycles | 91% vaccinated in vaccination group, none in unvaccinated group | Unknown | Unknown | Unvaccinated group | No significant differences |
| 16 | [67] | Retrospective cohort study | 13.5% Viral vector vaccine, 86.5% mRNA vaccine | 1700 IVF cycles | Unknown | Unknown | Approximately 2 months after the second dose | Self-control | No significant differences |
| 17 | [80] | Prospective cohort study | 1.6% Viral vector vaccine, 95.7% inactivated vaccine, 2.7% recombinant subunit vaccine | 4185 IUI cycles | 46.9% vaccinated | Unknown | 154 days after the first dose in clinical group, 146 days in nonclinical group | Unvaccinated group | No significant differences |
| 18 | [23] | Prospective cohort study | 93.7% Inactivated vaccine, 6.3% recombinant subunit vaccine | 554 IVF cycles | 91.1% vaccinated | No | <3 months (36.2%), 3-6 months (57.5%), and >6 months (6.3%) after complete vaccination | Unvaccinated group | No significant differences |
| 19 | [88] | Retrospective cohort study | Inactivated vaccine | 1000 IUI cycles | Unknown | Unknown | <3 months (27.3%), ≥3 months (72.7%) after the last dose | Unvaccinated group | No significant differences |
ART, assisted reproductive technology; IVF, in vitro fertilization; PGT, preimplantation genetic testing; IUI, Intrauterine insemination.